

Grzegorz S Nowakowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5724707/publications.pdf>

Version: 2024-02-01

249

papers

5,031

citations

117625

34

h-index

110387

64

g-index

250

all docs

250

docs citations

250

times ranked

6719

citing authors

#	ARTICLE	IF	CITATIONS
1	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Advances, 2022, 6, 1350-1360.	5.2	9
2	Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. International Journal of Hematology, 2022, 115, 222-232.	1.6	15
3	Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. Blood Cancer Journal, 2022, 12, 1.	6.2	7
4	What Prognostic Markers Should Be Evaluated in Marginal Zone Lymphoma? A Survey Among Leading International Experts. HemaSphere, 2022, 6, e680.	2.7	0
5	First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clinical Cancer Research, 2022, 28, 1285-1293.	7.0	16
6	67-Year-Old Woman With Diarrhea and Weight Loss. Mayo Clinic Proceedings, 2022, 97, 364-369.	3.0	0
7	Immune Epigenetic Crosstalk Between Malignant B Cells and the Tumor Microenvironment in B Cell Lymphoma. Frontiers in Genetics, 2022, 13, 826594.	2.3	6
8	Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. Current Treatment Options in Oncology, 2022, 23, 155-170.	3.0	17
9	Finding a consensus on time-to-event endpoints definitions in marginal zone lymphoma: A Delphi method. Hematological Oncology, 2022, 40, 1086-1089.	1.7	0
10	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e815-e825.	0.4	2
11	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. Blood Cancer Journal, 2022, 12, 78.	6.2	1
12	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. JCO Oncology Practice, 2022, , OP2100789.	2.9	0
13	<sc>RNAseq</sc> identification of <sc>FISH</sc> â€œcryptic <i> <sc>BCL6</sc> :: <sc>TP63</sc> </i> rearrangement in <sc>ALK</sc> â€œnegative anaplastic large cell lymphoma. Histopathology, 2022, , .	2.9	4
14	Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. Journal of Clinical Oncology, 2022, 40, 2163-2171.	1.6	68
15	Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).. Journal of Clinical Oncology, 2022, 40, 7560-7560.	1.6	0
16	Availability of data for screening, offering, and consenting patients to cancer clinical trials: Report from an ASCO-ACCC collaboration.. Journal of Clinical Oncology, 2022, 40, 6530-6530.	1.6	2
17	Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.. Journal of Clinical Oncology, 2022, 40, 7559-7559.	1.6	1
18	Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.. Journal of Clinical Oncology, 2022, 40, 3084-3084.	1.6	0

#	ARTICLE	IF	CITATIONS
19	frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2022, 40, TPS7590-TPS7590.	1.6	1
20	Pharmacokinetics (PK) and pharmacodynamics (PD) in First-MIND: A phase Ib, open-label, randomized study of tafasitamab (tafa) ± lenalidomide (LEN) in addition to R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2022, 40, e19553-e19553.	1.6	0
21	Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.. Journal of Clinical Oncology, 2022, 40, 7575-7575.	1.6	3
22	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clinical Cancer Research, 2022, 28, 4003-4017.	7.0	15
23	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia, 2021, 35, 522-533.	7.2	28
24	American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. Journal of Clinical Oncology, 2021, 39, 155-169.	1.6	65
25	Testicular ^{FDG}PET</sup>/^{CT} uptake threshold in aggressive lymphomas. American Journal of Hematology, 2021, 96, E81-E83.	4.1	3
26	Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. Blood Cancer Journal, 2021, 11, 8.	6.2	9
27	Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. International Journal of Cancer, 2021, 149, 535-545.	5.1	4
28	Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. Blood Advances, 2021, 5, 1379-1387.	5.2	18
29	Relapsed/Refractory International Prognostic Index (R^{IPI}): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. American Journal of Hematology, 2021, 96, 599-605.	4.1	8
30	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. Journal of Clinical Oncology, 2021, 39, 1329-1338.	1.6	60
31	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2021, 39, 1317-1328.	1.6	132
32	Diffuse large B-cell lymphoma: new targets and novel therapies. Blood Cancer Journal, 2021, 11, 68.	6.2	41
33	Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).. Journal of Clinical Oncology, 2021, 39, TPS7571-TPS7571.	1.6	2
34	Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2021, 39, e19501-e19501.	1.6	0
35	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.. Journal of Clinical Oncology, 2021, 39, e19547-e19547.	1.6	2
36	Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis.. Journal of Clinical Oncology, 2021, 39, 7542-7542.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2021, 39, e13569-e13569.	1.6	1
38	Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?. Journal of Clinical Oncology, 2021, 39, 7530-7530.	1.6	1
39	Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2021, 39, 7522-7522.	1.6	3
40	Impact of Organ Functionâ€‘Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. Journal of Clinical Oncology, 2021, 39, 1641-1649.	1.6	16
41	Outcomes in mantle cell lymphoma with central nervous system involvement.. Journal of Clinical Oncology, 2021, 39, e19527-e19527.	1.6	4
42	First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL.. Journal of Clinical Oncology, 2021, 39, 7540-7540.	1.6	8
43	Diffuse large B-cell lymphoma with leukemic involvement.. Journal of Clinical Oncology, 2021, 39, e19552-e19552.	1.6	0
44	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. American Journal of Hematology, 2021, 96, 979-988.	4.1	5
45	Safety and efficacy of VIP152, a CDK9 inhibitor, in patients with double-hit lymphoma (DHL).. Journal of Clinical Oncology, 2021, 39, 7538-7538.	1.6	4
46	Assessment of fixedâ€‘duration therapies for treatmentâ€‘naïve <sc>Waldenström</sc> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	4.1	12
47	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood Cancer Journal, 2021, 11, 133.	6.2	4
48	Lack of intrafollicular memory CD4â€‘+â€‘T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer Journal, 2021, 11, 130.	6.2	27
49	A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. Leukemia and Lymphoma, 2021, 62, 2625-2636.	1.3	3
50	RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2021, 27, 6124-6134.	7.0	24
51	Outcomes in primary cutaneous diffuse large Bâ€‘cell lymphoma, leg type. Hematological Oncology, 2021, 39, 658-663.	1.7	8
52	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	2.5	12
53	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. Blood Cancer Journal, 2021, 11, 160.	6.2	3
54	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. Blood, 2021, 138, 1415-1415.	1.4	1

#	ARTICLE	IF	CITATIONS
55	A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR) Tj ETQq1 1 0.784314 rgB5 /Overlook	1.4	1
56	Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 183-183.	1.4	8
57	Vaccination History and Risk of Lymphoma and Its Major Subtypes. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.0383.2021.	2.5	1
58	Central Nervous System Involvement By Mantle Cell Lymphoma. Blood, 2021, 138, 2426-2426.	1.4	1
59	Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress). Blood, 2021, 138, 3564-3564.	1.4	1
60	Mismatch-Repair Deficiency in Follicular Lymphoma Tumors Is Common and Associated with a Favorable Overall Survival. Blood, 2021, 138, 3523-3523.	1.4	0
61	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. Blood, 2021, 138, 1373-1373.	1.4	2
62	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. Blood, 2021, 138, 2429-2429.	1.4	1
63	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. Blood, 2021, 138, 1452-1452.	1.4	0
64	The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models. Blood, 2021, 138, 2412-2412.	1.4	2
65	Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes. Blood, 2021, 138, 2524-2524.	1.4	1
66	Impact of Diagnosis-to-Treatment Interval on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis. Blood, 2021, 138, 3549-3549.	1.4	0
67	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. Blood, 2021, 138, 2508-2508.	1.4	0
68	A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 52-52.	1.4	3
69	First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 3556-3556.	1.4	2
70	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. Blood, 2021, 138, 2527-2527.	1.4	3
71	Recently approved drugs herald a new era in therapy for diffuse large B-cell lymphoma. Clinical Advances in Hematology and Oncology, 2021, 19, 284-287.	0.3	1
72	Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. Haematologica, 2020, 105, e72-e75.	3.5	11

#	ARTICLE	IF	CITATIONS
73	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. <i>Haematologica</i> , 2020, 105, 348-357.	3.5	105
74	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. <i>Leukemia and Lymphoma</i> , 2020, 61, 318-327.	1.3	9
75	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1221-1228.	5.8	22
76	Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract. <i>Leukemia</i> , 2020, 34, 1467-1471.	7.2	7
77	Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	4.1	33
78	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.	1.3	2
79	Holistic review for hematology oncology fellowship applicants: A new paradigm?. <i>American Journal of Hematology</i> , 2020, 95, 1124-1126.	4.1	1
80	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117.	6.2	18
81	Analysis and impact of a multidisciplinary lymphoma virtual tumor board. <i>Leukemia and Lymphoma</i> , 2020, 61, 3351-3359.	1.3	14
82	Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2012534.	5.9	72
83	Treatment of Aggressive B Cell Lymphomas: Updates in 2019. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 225-234.	2.3	7
84	A practical approach to FISH testing for MYC rearrangements and brief review of MYC in aggressive B-cell lymphomas. <i>Journal of Hematopathology</i> , 2020, 13, 127-135.	0.4	2
85	ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1. <i>Future Oncology</i> , 2020, 16, 991-999.	2.4	12
86	A Graduate-Level Interdisciplinary Curriculum in CAR-T Cell Therapy. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 203-210.	2.4	10
87	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase. <i>Blood</i> , 2020, 136, 27-28.	1.4	2
88	Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study. <i>Blood</i> , 2020, 136, 44-45.	1.4	8
89	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020, 136, 7-8.	1.4	2
90	RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). <i>Journal of Clinical Oncology</i> , 2020, 38, 8020-8020.	1.6	11

#	ARTICLE	IF	CITATIONS
91	Mayo Clinic Hematology Fellowship for Advanced Practice Providers. Journal of the Advanced Practitioner in Oncology, 2020, 11, 395-400.	0.4	1
92	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. Blood, 2020, 136, 3-4.	1.4	1
93	Estimation of Long-Term Survival with Tafasitamab + Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 9-10.	1.4	0
94	A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies. Blood, 2020, 136, 49-50.	1.4	1
95	Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. Blood, 2020, 136, 47-48.	1.4	0
96	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 26-27.	1.4	1
97	Waldenström Macroglobulinemia in the Very Elderly (≥75 years): Clinical Characteristics and Outcomes. Blood, 2020, 136, 44-45.	1.4	8
98	A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses. Leukemia and Lymphoma, 2019, 60, 559-561.	1.3	9
99	T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes. British Journal of Haematology, 2019, 185, 140-142.	2.5	9
100	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood, 2019, 134, 1289-1297.	1.4	26
101	End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma. PET Clinics, 2019, 14, 307-315.	3.0	8
102	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 73.	6.2	37
103	Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. Journal of Clinical Oncology, 2019, 37, 1819-1827.	1.6	44
104	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. British Journal of Haematology, 2019, 186, 820-828.	2.5	12
105	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 48.	6.2	24
106	Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. American Journal of Hematology, 2019, 94, 786-793.	4.1	15
107	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. JAMA Oncology, 2019, 5, 1008.	7.1	526
108	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. Journal of Clinical Oncology, 2019, 37, 1188-1199.	1.6	277

#	ARTICLE	IF	CITATIONS
109	<p>Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy</p>. Clinical Epidemiology, 2019, Volume 11, 987-996.	3.0	5
110	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia, 2019, 33, 790-794.	7.2	28
111	Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018. American Journal of Hematology, 2019, 94, 291-298.	4.1	40
112	Identification of Factors Associated with Hematology-Oncology Fellow Academic Success and Career Choice. Journal of Cancer Education, 2019, 34, 1219-1224.	1.3	10
113	Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Blood, 2019, 134, 347-347.	1.4	2
114	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. Blood, 2019, 134, 4092-4092.	1.4	4
115	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). Blood, 2019, 134, 400-400.	1.4	2
116	Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1. Blood, 2019, 134, 5330-5330.	1.4	1
117	A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood, 2019, 134, 467-467.	1.4	29
118	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. Blood, 2019, 134, 121-121.	1.4	7
119	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial. Blood, 2019, 134, 2877-2877.	1.4	3
120	Coplanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study. Blood, 2019, 134, 4090-4090.	1.4	1
121	Comparative Assessment of Surface CD19 and CD20 Expression on B-Cell Lymphomas from Clinical Biopsies: Implications for Targeted Therapies. Blood, 2019, 134, 5345-5345.	1.4	24
122	Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro. Blood, 2019, 134, 2859-2859.	1.4	9
123	Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience. Blood, 2019, 134, 4129-4129.	1.4	1
124	Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information. Blood, 2019, 134, 5327-5327.	1.4	4
125	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. Blood, 2019, 134, 1532-1532.	1.4	0
126	Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study. Blood, 2019, 134, 3475-3475.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy. <i>Blood</i> , 2019, 134, 5352-5352.	1.4	0
128	Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients. <i>Blood</i> , 2019, 134, 5215-5215.	1.4	0
129	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 919-919.	1.4	0
130	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. <i>Blood</i> , 2019, 134, 923-923.	1.4	0
131	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , 2019, 134, 1480-1480.	1.4	0
132	Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 1604-1604.	1.4	3
133	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era. <i>Blood</i> , 2019, 134, 422-422.	1.4	0
134	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5293-5293.	1.4	2
135	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018, 93, 57-68.	2.8	90
136	Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. <i>Blood Cancer Journal</i> , 2018, 8, 27.	6.2	10
137	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018, 183, 149-152.	2.5	5
138	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	1.6	93
139	Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?. <i>Nutrition and Cancer</i> , 2018, 70, 1088-1090.	2.0	4
140	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018, 182, 644-653.	2.5	20
141	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , 2018, 8, 63.	6.2	22
142	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , 2018, 8, 73.	6.2	26
143	The diagnosis and treatment of primary vitreoretinal lymphoma: a review. <i>International Journal of Retina and Vitreous</i> , 2018, 4, 18.	1.9	85
144	Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 57.	17.0	19

#	ARTICLE	IF	CITATIONS
145	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. <i>Haematologica</i> , 2018, 103, 1899-1907.	3.5	52
146	A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 664-672.e2.	0.4	6
147	AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 445-445.	1.4	9
148	An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation. <i>Blood</i> , 2018, 132, 2247-2247.	1.4	2
149	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2018, 132, 454-454.	1.4	1
150	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. <i>Blood</i> , 2018, 132, 4204-4204.	1.4	1
151	Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 4168-4168.	1.4	8
152	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials. <i>Blood</i> , 2018, 132, 2962-2962.	1.4	1
153	Lenalidomide in Combination with Standard R-CHOP Overcomes the Negative Prognostic Value of Peripheral Blood Absolute Lymphocyte/Monocyte Ratio at Diagnosis and during Treatment in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 4139-4139.	1.4	0
154	Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas. <i>Blood</i> , 2018, 132, 5401-5401.	1.4	1
155	Non-Diffuse Large B-Cell Primary Central Nervous System Lymphoma. <i>Blood</i> , 2018, 132, 4208-4208.	1.4	0
156	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.	1.4	1
157	Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. <i>Blood</i> , 2018, 132, 2979-2979.	1.4	0
158	Development of a Hematology-Specific Fellowship Curriculum for Advanced Practice Providers Utilizing a Needs-Based Assessment. <i>Blood</i> , 2018, 132, 2236-2236.	1.4	0
159	Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era. <i>Blood</i> , 2018, 132, 4140-4140.	1.4	0
160	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 448-453.	4.1	26
161	Recent advances in clinical studies and the evolving role of subtyping for patients with diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2017, 13, 859-862.	2.4	4
162	Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 427-433.	2.5	15

#	ARTICLE	IF	CITATIONS
163	Diagnosis and Management of Waldenström Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	7.1	110
164	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. International Journal of Epidemiology, 2017, 46, 1753-1754i.	1.9	57
165	Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab. American Journal of Hematology, 2017, 92, 1156-1162.	4.1	8
166	Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. British Journal of Haematology, 2017, 179, 50-60.	2.5	49
167	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget, 2017, 8, 27145-27154.	1.8	55
168	Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma. Oncotarget, 2017, 8, 26245-26255.	1.8	14
169	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future Oncology, 2016, 12, 1553-1563.	2.4	85
170	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. Journal of the National Cancer Institute, 2016, 108, djw257.	6.3	56
171	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. American Journal of Hematology, 2016, 91, 1096-1101.	4.1	180
172	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. Blood, 2016, 128, 1104-1104.	1.4	1
173	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). Blood, 2016, 128, 155-155.	1.4	1
174	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 1874-1874.	1.4	2
175	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies. Blood, 2016, 128, 3033-3033.	1.4	2
176	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. Blood, 2016, 128, 3034-3034.	1.4	5
177	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 3035-3035.	1.4	5
178	Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. Blood, 2016, 128, 3036-3036.	1.4	0
179	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study. Blood, 2016, 128, 5322-5322.	1.4	0
180	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2935-2935.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Retinoic Acid Receptor Alpha Expression Drives Cell-Cycle Progression and Is Associated with Increased Sensitivity to Retinoids in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1749-1749.	1.4	0
182	The efficacy of ibrutinib in the treatment of Richter syndrome. <i>Blood</i> , 2015, 125, 1676-1678.	1.4	83
183	A roadmap for discovery and translation in lymphoma. <i>Blood</i> , 2015, 125, 2175-2177.	1.4	18
184	Evolution: IMiDs to PPMs, revolution in DLBCL?. <i>Blood</i> , 2015, 126, 698-700.	1.4	5
185	ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e449-e457.	3.8	102
186	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. <i>Blood</i> , 2015, 126, 328-335.	1.4	92
187	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 699-704.	0.4	11
188	Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 1658-1671.	4.1	122
189	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015, 20, 1149-1153.	3.7	52
190	Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non-Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 251-257.	1.6	319
191	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2683-2683.	1.4	6
192	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 3992-3992.	1.4	1
193	Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance). <i>Blood</i> , 2015, 126, 813-813.	1.4	1
194	Randomized, phase III trial of the efficacy and safety of lenalidomide plus R-CHOP vs R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS8600-TPS8600.	1.6	1
195	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. <i>Blood</i> , 2015, 126, 3730-3730.	1.4	0
196	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 131-131.	1.4	0
197	Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3885-3885.	1.4	0
198	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. <i>Blood</i> , 2015, 126, 2490-2490.	1.4	0

#	ARTICLE	IF	CITATIONS
199	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. <i>Blood</i> , 2015, 126, 4993-4993.	1.4	0
200	Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 1456-1456.	1.4	0
201	Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 2862-2872.	7.0	86
202	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	6.2	96
203	Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Journal of Clinical Oncology</i> , 2013, 31, 3272-3278.	1.6	259
204	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 4306-4306.	1.4	0
205	Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study. <i>Blood</i> , 2012, 120, 689-689.	1.4	8
206	Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution. <i>Blood</i> , 2012, 120, 1525-1525.	1.4	0
207	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL). <i>Blood</i> , 2012, 120, 1527-1527.	1.4	0
208	The Presence of Intratumoral CD14 Positive Cells Is Associated with Transformation of Follicular Lymphoma to Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2012, 120, 2700-2700.	1.4	31
209	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2012, 120, 684-684.	1.4	0
210	LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.. <i>Blood</i> , 2012, 120, 2741-2741.	1.4	0
211	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012, 120, 149-149.	1.4	0
212	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. <i>Blood</i> , 2012, 120, 1563-1563.	1.4	0
213	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL).. <i>Blood</i> , 2012, 120, 2634-2634.	1.4	0
214	Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment “a Single Institution Experience. <i>Blood</i> , 2011, 118, 1580-1580.	1.4	1
215	Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy. <i>Blood</i> , 2011, 118, 1640-1640.	1.4	1
216	Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab. <i>Blood</i> , 2011, 118, 2836-2836.	1.4	1

#	ARTICLE	IF	CITATIONS
217	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma,. Blood, 2011, 118, 3652-3652.	1.4	0
218	Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients. Blood, 2011, 118, 1926-1926.	1.4	0
219	Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience. Blood, 2011, 118, 1572-1572.	1.4	0
220	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,. Blood, 2011, 118, 3642-3642.	1.4	0
221	The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma. Blood, 2011, 118, 85-85.	1.4	1
222	Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies. Blood, 2011, 118, 2682-2682.	1.4	0
223	Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylooxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG. Blood, 2011, 118, 880-880.	1.4	2
224	Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era. Journal of Clinical Oncology, 2010, 28, 412-417.	1.6	75
225	Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma.. Blood, 2010, 116, 2802-2802.	1.4	2
226	A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas. Blood, 2010, 116, 287-287.	1.4	5
227	Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes â€” Single Institution Experience. Blood, 2010, 116, 4168-4168.	1.4	5
228	Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 996-996.	1.4	2
229	The Absolute Monocyte and Lymphocyte Counts at Diagnosis Predict Survival and Identify High-Risk Patients In Diffuse Large-B-Cell Lymphoma. Blood, 2010, 116, 3088-3088.	1.4	0
230	Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival. Blood, 2010, 116, 4136-4136.	1.4	0
231	Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target. Blood, 2010, 116, 3115-3115.	1.4	0
232	Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma. Blood, 2010, 116, 2862-2862.	1.4	0
233	Reply to R.S. Go. Journal of Clinical Oncology, 2009, 27, e45-e45.	1.6	1
234	Percentage of Smudge Cells on Routine Blood Smear Predicts Survival in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2009, 27, 1844-1849.	1.6	71

#	ARTICLE	IF	CITATIONS
235	Somatic Hyperrepair: A Novel Tumor Suppression Mechanism for Germinal Center B Cells.. Blood, 2009, 114, 92-92.	1.4	2
236	Cytogenetic Analysis of Normal Human B Cells Following CpG Stimulation: Implications for Interpretation of CpG Induced CLL Metaphase Analysis. Blood, 2008, 112, 3124-3124.	1.4	2
237	Using Smudge Cells on Routine Blood Smears to Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test. Mayo Clinic Proceedings, 2007, 82, 449-453.	3.0	55
238	Crosstalk between Chronic Lymphocytic Leukemia (CLL) B-Cells and Marrow Stromal Cells: Implication for CLL B-Cell Activation and Survival.. Blood, 2007, 110, 337-337.	1.4	1
239	Increased Cytotoxic T-Cell Infiltrates in the Bone Marrow Is an Independent Adverse Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.. Blood, 2007, 110, 1492-1492.	1.4	0
240	A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer. Clinical Cancer Research, 2006, 12, 6087-6093.	7.0	112
241	Smudge Cells on Routine Blood Smear Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test.. Blood, 2006, 108, 2785-2785.	1.4	1
242	Initial Presentation and Prognostic Factors in 286 Patients with T-Cell Large Granular Lymphocyte Leukemia.. Blood, 2006, 108, 300-300.	1.4	5
243	Neuropilin-1 Receptor (NRP-1) Occupancy Induces Cell Death in Primary Chronic Lymphocytic Leukemia (CLL) B Cells.. Blood, 2006, 108, 586-586.	1.4	0
244	Human leucocyte antigen class I and killer immunoglobulin-like receptor expression patterns in T-cell large granular lymphocyte leukaemia. British Journal of Haematology, 2005, 128, 490-492.	2.5	20
245	Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease.. Blood, 2005, 106, 707-707.	1.4	14
246	Prognostic Factors and Survival of Patients with Primary Mediastinal Large B-Cell Lymphoma.. Blood, 2005, 106, 4698-4698.	1.4	0
247	Targeting Vla-4 Reduces Cell Adhesion Mediated Drug Resistance in Chronic Lymphocytic Leukemia: Rationale for Anti Vla-4 Therapy.. Blood, 2005, 106, 1182-1182.	1.4	0
248	Interphase Fluorescence In Situ Hybridization (FISH) with an IgH Probe Is Important in the Management of Patients with a Clinical Diagnosis of Chronic Lymphocytic Leukemia (CLL).. Blood, 2004, 104, 1919-1919.	1.4	1
249	Acquired Pure Red Cell Aplasia Associated with Clonal T-Cell Receptor (TCR) Gene Rearrangements with and without Pathologic Features of T-Cell Large Granular Lymphocytic Leukemia (T-LGL).. Blood, 2004, 104, 2819-2819.	1.4	0